10 completed, 4 recruiting, 2 not yet recruiting, 1 active not recruiting. 10 Phase 2, 5 Phase 3, 1 Phase 1, 1 Phase 4.
By phase and status
Follow maralixibat: new trials by email Literature Review of maralixibat trials Research Report on maralixibat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP) Maralixibat - Intrahepatic Cholestasis of Pregnancy | Phase 2 | Not yet recruiting | 15 | 2027-01-15 | 2026-09-16 |
Maralixibat for Intrahepatic Cholestasis of Pregnancy Maralixibat - Intrahepatic Cholestasis of Pregnancy | Phase 2 | Not yet recruiting | 28 | 2026-04-01 | 2026-02-05 |
A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat - Alagille Syndrome (ALGS), Progressive Familial Intrahepatic Cholestasis (PFIC) | | Recruiting | 50 | 2026-01-13 | 2026-02-20 |
Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU) Livmarli Oral Product - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | Phase 4 | Recruiting | 230 | 2025-09-25 | 2026-06-23 |
Maralixibat in Patients With Cystic Fibrosis and Constipation Maralixibat 9.5 MG/ML [Livmarli] - Constipation Chronic Idiopathic, Cystic Fibrosis | Phase 2 / Phase 3 | Recruiting | 20 | 2025-04-09 | 2026-04-21 |
Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) Maralixibat, Placebo - Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC) | Phase 3 | Active not recruiting | 90 | 2024-10-14 | 2026-11-13 |
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) Livmarli - Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis | | Recruiting | 70 | 2023-09-21 | 2026-11-13 |
A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). Maralixibat - Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome | Phase 2 | Completed | 27 | 2021-09-09 | 2026-06-02 |
Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai Maralixibat, Placebo - Biliary Atresia | Phase 2 | Completed | 75 | 2021-07-08 | 2025-03-19 |
MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study Maralixibat - Cholestatic Liver Disease | Phase 2 | Completed | 52 | 2020-01-16 | 2025-12-08 |
An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat - Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | Completed | 84 | 2020-01-08 | 2026-06-23 |
A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) Maralixibat, Placebo - Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | Completed | 93 | 2019-07-09 | 2023-12-11 |
A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC) Maralixibat, Placebo - Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 3 | Withdrawn | | 2018-10-25 | 2019-03-18 |
Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion Placebo, Maralixibat, Volixibat - Healthy Volunteers | Phase 1 | Completed | 84 | 2015-06-01 | 2019-04-04 |
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome LUM001 (Maralixibat) - Alagille Syndrome | Phase 2 | Completed | 34 | 2015-03-16 | 2021-07-01 |
Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) LUM001 (Maralixibat), Placebo - Alagille Syndrome | Phase 2 | Completed | 31 | 2014-10-28 | 2021-07-14 |
Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis LUM001 (Maralixibat) - Progressive Familial Intrahepatic Cholestasis (PFIC) | Phase 2 | Completed | 33 | 2014-03-01 | 2023-10-23 |
An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) LUM001 (Maralixibat) - Alagille Syndrome | Phase 2 | Completed | 19 | 2013-12-20 | 2021-11-19 |
A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS) maralixibat - Alagille Syndrome | | Approved for marketing | | | 2021-10-20 |
Conditions studied
Alagille Syndrome (8) · Cholestasis, progressive familial intrahepatic 1 (8) · Bile Duct Diseases (7) · Cholestasis (7) · Liver Diseases (7) · Biliary Tract Diseases (6) · Pruritus (5) · Digestive System Diseases (4) · Biliary Atresia (2) · Intrahepatic Cholestasis of Pregnancy (2) · Cholangitis, Sclerosing (1) · Cholestasis, Intrahepatic (1) · Congenital Abnormalities (1) · Cystic Fibrosis (1)
Sponsors
Mirum Pharmaceuticals, Inc. (16) · Children's Hospital Los Angeles (1) · Imperial College London (1) · Takeda (1)
Countries
United States (12) · United Kingdom (10) · France (8) · Poland (8) · Belgium (6) · Canada (5) · Germany (5) · Brazil (4) · Italy (4) · Spain (4) · Lebanon (3) · Mexico (3) · Singapore (3) · Argentina (2) · Australia (2)
Top investigators
Catherine Williamson, MD (1) · Jaya Punati, MD (1)
Results publications
PMID 42002216, PMID 34755627, PMID 35507739, PMID 36096175, PMID 38723644
NIH funding
2017 (1), 2019 (1)